Conformationally constrained peptides as protein tyrosine kinase inhibitors

Current Pharmaceutical Design

Volumn 18, Issue 20, 2012, Pages 2852-2866

  Tiwari, Rakesh K ^a   Parang, Keykavous ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Cyclization; Inhibitor; Peptide; Protein kinase; Selectivity; SH2 domain; SH3 domain; Tyrosine kinase

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; 6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ADENOSINE TRIPHOSPHATE; AEW 541; AP 22408; AP 22650; AP 22674; AZM 475271; BRIVANIB ALANINATE; CAPROLACTAM DERIVATIVE; CYCLOPEPTIDE; ERLOTINIB; GEFITINIB; HYDROXYL GROUP; IMATINIB; LENVATINIB; LINIFANIB; PEPTIDASE; PEPTIDE DERIVATIVE; PHOSPHATE; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; PROTEIN SH2; PROTEIN SH3; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PROTEINASE; RAPAMYCIN; SERINE; SORAFENIB; STAUROSPORINE; SUNITINIB; TETRAPEPTIDE; THREONINE; TIVOZANIB; TYROSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB;

ARTICLE; BINDING AFFINITY; BINDING SITE; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHRONIC MYELOID LEUKEMIA; CONGESTIVE HEART FAILURE; CYCLIZATION; DEGENERATIVE DISEASE; DRUG DESIGN; DRUG FATALITY; DRUG INDUSTRY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENERGY; ENTROPY; ENZYME MECHANISM; ENZYME SUBSTRATE COMPLEX; GASTROINTESTINAL STROMAL TUMOR; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYDROLYSIS; IC 50; INFLAMMATION; LIGAND BINDING; LUNG TOXICITY; METASTATIC MELANOMA; NEOPLASM; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; SIDE EFFECT;

EID: 84861754169     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212800672714     Document Type: Article

References (135)

1. Manning BD, Cantley LC. Hitting the target: emerging technologies in the search for kinase substrates. Sci STKE 2002; 2002: pe49.
2. Manning G, Plowman GD, Hunter T, Sudarsanam S. Evolution of protein kinase signaling from yeast to man. Trends Biochem Sci 2002; 27: 514-20.
3. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298: 1912-34.
4. Hunter T. Signaling--2000 and beyond. Cell 2000; 100: 113-27.
5. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411: 355-65.
6. Cohen P. Protein kinases--the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002; 1: 309-15.
7. Saltiel AR, Pessin JE. Insulin signaling pathways in time and space. Trends Cell Biol 2002; 12: 65-71.
8. Uckun FM, Mao C. Tyrosine kinases as new molecular targets in treatment of inflammatory disorders and leukemia. Curr Pharm Des 2004; 10: 1083-91.
9. Levitzki A. Protein kinase inhibitors as a therapeutic modality. Acc Chem Res 2003; 36: 462-9.
10. Jiang G, Zhang BB. Pi 3-kinase and its up-and down-stream modulators as potential targets for the treatment of type II diabetes. Front Biosci 2002; 7: d903-7.
11. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001; 359: 1-16.
12. Vlahos CJ, McDowell SA, Clerk A. Kinases as therapeutic targets for heart failure. Nat Rev Drug Discov 2003; 2: 99-113.
13. Force T, Kuida K, Namchuk M, Parang K, Kyriakis JM. Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease. Circulation 2004; 109: 1196-205.
14. Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 2000; 47: 185-201.
15. Traxler P. Tyrosine kinases as targets in cancer therapy-successes and failures. Expert Opin Ther Targets 2003; 7: 215-34.
16. Druker BJ. Imatinib alone and in combination for chronic myeloid leukemia. Semin Hematol 2003; 40: 50-8.
17. Wakeling AE. Epidermal growth factor receptor tyrosine kinase inhibitors. Curr Opin Pharmacol 2002; 2: 382-7.
18. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001; 104: 852-5.
19. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
20. Mitchell P. Erbitux diagnostic latest adjunct to cancer therapy. Nat Biotechnol 2004; 22: 363-4.
21. Roskoski R, Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004; 319: 1-11.
22. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.
23. Gambacorti-Passerini C. Part I: Milestones in personalised medicine-imatinib. Lancet Oncology 2008; 9: 600-600.
24. Das J, Chen P, Norris D, et al. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem 2006; 49: 6819-6832.
25. Das J, Chen P, Lombardo LJ, et al. MEDI 295-2-Aminothiazole: A novel template for the discovery of Dasatinib (BMS-354825), a pan Src/Abl kinase inhibitor. Abstracts of Papers of the American Chemical Society 2006; 232.
26. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinibresistant Philadelphia chromosome-positive leukemias. New England Journal of Medicine 2006; 354: 2531-2541.
27. Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. Journal of Clinical Endocrinology & Metabolism 2006; 91: 4070-4076.
28. Chow LQM, Eckhardt SG. Sunitinib: From rational design to clinical efficacy. Journal of Clinical Oncology 2007; 25: 884-896.
29. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
30. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncology 2009; 10: 25-34.
31. Shilling AD, Nedza FM, Emm T, et al. Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. Drug Metab Dispos 2010; 38: 2023-31.
32. Mesa RA. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. IDrugs 2010; 13: 394-403.
33. Formica RN, Jr., Lorber KM, Friedman AL, Bia MJ, Lakkis F, Smith JD, Lorber MI. The evolving experience using everolimus in clinical transplantation. Transplant Proc 2004; 36: 495S-499S.
34. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009; 27: 3126-32.
35. Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000; 60 Suppl 1: 15-23; discussion 41-2.
36. Pao W, Ladanyi M, Miller VA, Lung Cancer Oncogenome G. Erlotinib in lung cancer. N Engl J Med 2005; 353: 1739-41; author reply 1739-41.
37. Shaw AT, Yasothan U, Kirkpatrick P. Crizotinib. Nat Rev Drug Discov 2011; 10: 897-8.
38. Shaw AT, Solomon B, Kenudson MM. Crizotinib and Testing for ALK. J Natl Compr Canc Netw 2011; 9: 1335-41.
39. Koch L. Pharmacotherapy: Vandetanib-a new therapeutic option in advanced medullary thyroid cancer. Nat Rev Endocrinol 2011; 8: 1.
40. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinibresistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542-51.
41. Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. AMN107 (nilotinib): a novel and selective inhibitor of BCRABL. Br J Cancer 2006; 94: 1765-9.
42. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467: 596-9.
43. Rubio-Viqueira B, Hidalgo M. Targeting mTOR for cancer treatment. Adv Exp Med Biol 2006; 587: 309-27.
44. Del Bufalo D, Ciuffreda L, Trisciuoglio D, et al. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006; 66: 5549-54.
45. Minkovsky N, Berezov A. BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Investig Drugs 2008; 9: 1336-46.
46. Hirsh V. Afatinib (BIBW 2992) development in non-small-cell lung cancer. Future Oncol 2011; 7: 817-25.
47. Bajpai M. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases. IDrugs 2009; 12: 174-85.
48. Genovese MC, Kavanaugh A, Weinblatt ME, et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a threemonth randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 2011; 63: 337-45.
49. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008; 14: 5459-65.
50. Gild ML, Bullock M, Robinson BG, Clifton-Bligh R. Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat Rev Endocrinol 2011; 7: 617-24.
51. Huynh H, Ngo VC, Fargnoli J, et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008; 14: 6146-53.
52. Hedvat M, Huszar D, Herrmann A, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009; 16: 487-97.
53. Albert DH, Tapang P, Magoc TJ, et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 2006; 5: 995-1006.
54. Garcia-Echeverria C, Pearson MA, Marti A, et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004; 5: 231-9.
55. Nakamura K, Taguchi E, Miura T, et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res 2006; 66: 9134-42.
56. Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclindependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004; 3: 1427-38.
57. Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Annu Rev Biochem 2000; 69: 373-98.
58. Warmuth M, Damoiseaux R, Liu Y, Fabbro D, Gray N. SRC family kinases: potential targets for the treatment of human cancer and leukemia. Curr Pharm Des 2003; 9: 2043-59.
59. Susa M, Teti A. Tyrosine kinase src inhibitors: potential therapeutic applications. Drug News Perspect 2000; 13: 169-75.
60. Hubbard SR. Protein tyrosine kinases: autoregulation and smallmolecule inhibition. Curr Opin Struct Biol 2002; 12: 735-741.
61. Scapin G. Structural biology in drug design: selective protein kinase inhibitors. Drug Discov Today 2002; 7: 601-611.
62. Williams DH, Mitchell T. Latest developments in crystallography and structure-based design of protein kinase inhibitors as drug candidates. Curr Opin Pharmacol 2002; 2: 567-73.
63. Xu W, Harrison SC, Eck MJ. Three-dimensional structure of the tyrosine kinase c-Src. Nature 1997; 385: 595-602.
64. Xu W, Doshi A, Lei M, Eck MJ, Harrison SC. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell 1999; 3: 629-38.
65. Sawyer TK. Src homology-2 domains: structure, mechanisms, and drug discovery. Biopolymers 1998; 47: 243-61.
66. Songyang Z, Shoelson SE, Chaudhuri M, et al. SH2 domains recognize specific phosphopeptide sequences. Cell 1993; 72: 767-78.
67. Sicheri F, Moarefi I, Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature 1997; 385: 602-609.
68. Sicheri F, Kuriyan J. Structures of Src-family tyrosine kinases. Curr Opin Struct Biol 1997; 7: 777-85.
69. Taylor SS, Radzio-Andzelm E. Three protein kinase structures define a common motif. Structure 1994; 2: 345-55.
70. Wu SY, McNae I, Kontopidis G, et al. Discovery of a novel family of CDK inhibitors with the program LIDAEUS: Structural basis for ligand-induced disordering of the activation loop. Structure 2003; 11: 399-410.
71. Ghoreschi K, Laurence A, O'Shea JJ. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol 2009; 10: 356-60.
72. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9: 28-39.
73. Davis MI, Hunt JP, Herrgard S, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011; 29: 1046-51.
74. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochemical Journal 2003; 371: 199-204.
75. Cheng H, Kari G, Dicker AP, Rodeck U, Koch WJ, Force T. A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. Circ Res 2011; 109: 1401-9.
76. Cheng H, Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res 2010; 106: 21-34.
77. Peerzada MM, Spiro TP, Daw HA. Pulmonary toxicities of biologics: a review. Anticancer Drugs 2010; 21: 131-9.
78. Lavoie H, Therrien M. Cancer: A drug-resistant duo. Nature 2011; 480: 329-30.
79. Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908-16.
80. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011-9.
81. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 5204-12.
82. Peerzada MM, Spiro TP, Daw HA. Pulmonary toxicities of tyrosine kinase inhibitors. Clin adv Hematol Oncol 2011; 9: 824-36.
83. Kobayashi S, Ji H, Yuza Y, et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 2005; 65: 7096-101.
84. Chu S, Xu H, Shah NP, et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005; 105: 2093-8.
85. Hughes T, Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev 2006; 20: 29-41.
86. Roumiantsev S, Shah NP, Gorre ME, et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA 2002; 99: 10700-5.
87. Fletcher JA, Rubin BP. KIT mutations in GIST. Curr Opin Genet Dev 2007; 17: 3-7.
88. Cools J, Mentens N, Furet P, et al. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res 2004; 64: 6385-9.
89. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276-83.
90. le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000; 95: 1758-66.
91. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
92. Harrison S, Das K, Karim F, Maclean D, Mendel D. Non-ATPcompetitive kinase inhibitors-enhancing selectivity through new inhibition strategies. Expert Opinion on Drug Discovery 2008; 3: 761-774.
93. Ye G, Tiwari R, Parang K. Development of Src tyrosine kinase substrate binding site inhibitors. Curr Opin Investig Drugs 2008; 9: 605-13.
94. Humphrey JM, Chamberlin AR. Chemical Synthesis of Natural Product Peptides: Coupling Methods for the Incorporation of Noncoded Amino Acids into Peptides. Chem Rev 1997; 97: 2243-2266.
95. Khan AR, Parrish JC, Fraser ME, Smith WW, Bartlett PA, James MN. Lowering the entropic barrier for binding conformationally flexible inhibitors to enzymes. Biochemistry 1998; 37: 16839-45.
96. Smith WW, Bartlett PA. Macrocyclic inhibitors of penicillopepsin. 3. Design, synthesis, and evaluation of an inhibitor bridged between P2 and P1 '. J Am Chem Soc 1998; 120: 4622-4628.
97. Davidson JP, Lubman O, Rose T, Waksman G, Martin SF. Calorimetric and structural studies of 1,2,3-trisubstituted cyclopropanes as conformationally constrained peptide inhibitors of Src SH2 domain binding. J Am Chem Soc 2002; 124: 205-15.
98. Marastoni M, Salvadori S, Balboni G, et al. Structure-activity relationships of cyclic and linear peptide T analogues. Int J Pept Protein Res 1993; 41: 447-54.
99. Szewczuk Z, Stefanowicz P, Wilczynski A, et al. Immunosuppressory activity of ubiquitin fragments containing retro-RGD sequence. Biopolymers 2004; 74: 352-62.
100. White CJ, Yudin AK. Contemporary strategies for peptide macrocyclization. Nat Chem 2011; 3: 509-24.
101. Clark RJ, Craik DJ. Native chemical ligation applied to the synthesis and bioengineering of circular peptides and proteins. Biopolymers 2010; 94: 414-22.
102. Jiang S, Li Z, Ding K, Roller PP. Recent Progress of Synthetic Studies to Peptide and Peptidomimetic Cyclization. Current Organic Chemistry 2008; 12: 1502-1542.
103. Katsara M, Tselios T, Deraos S, et al. Round and round we go: Cyclic peptides in disease. Current Medicinal Chemistry 2006; 13: 2221-2232.
104. Davies JS. The cyclization of peptides and depsipeptides. Journal of Peptide Science 2003; 9: 471-501.
105. Lambert JN, Mitchell JP, Roberts KD. The synthesis of cyclic peptides. Journal of the Chemical Society-Perkin Transactions 1 2001: 471-484.
106. Parang K, Sun G. Design strategies for protein kinase inhibitors. Curr Opin Drug Discov Devel 2004; 7: 617-29.
107. Parang K, Sun GQ. Recent advances in the discovery of Src kinase inhibitors. Expert Opinion on Therapeutic Patents 2005; 15: 1183-1207.
108. Omura S, Iwai Y, Hirano A, et al. New Alkaloid Am-2282 of Streptomyces Origin Taxonomy, Fermentation, Isolation and Preliminary Characterization. Journal of Antibiotics 1977; 30: 275-282.
109. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127-32.
110. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975; 28: 721-6.
111. Waksman G, Kominos D, Robertson SC, et al. Crystal structure of the phosphotyrosine recognition domain SH2 of v-src complexed with tyrosine-phosphorylated peptides. Nature 1992; 358: 646-53.
112. Ettmayer P, France D, Gounarides J, et al. Structural and conformational requirements for high-affinity binding to the SH2 domain of Grb2(1). J Med Chem 1999; 42: 971-80.
113. Lesuisse D, Lange G, Deprez P, et al. SAR and X-ray. A new approach combining fragment-based screening and rational drug design: application to the discovery of nanomolar inhibitors of Src SH2. J Med Chem 2002; 45: 2379-87.
114. Shakespeare W, Yang M, Bohacek R, et al. Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity. Proc Natl Acad Sci USA 2000; 97: 9373-8.
115. Sundaramoorthi R, Kawahata N, Yang MG, et al. Structure-based design of novel nonpeptide inhibitors of the Src SH2 domain:phosphotyrosine mimetics exploiting multifunctional group replacement chemistry. Biopolymers 2003; 71: 717-29.
116. Nam NH, Ye G, Sun G, Parang K. Conformationally constrained peptide analogues of pTyr-Glu-Glu-Ile as inhibitors of the Src SH2 domain binding. J Med Chem 2004; 47: 3131-41.
117. Rickles RJ, Botfield MC, Zhou XM, Henry PA, Brugge JS, Zoller MJ. Phage display selection of ligand residues important for Src homology 3 domain binding specificity. Proc Natl Acad Sci USA 1995; 92: 10909-13.
118. Feng S, Kasahara C, Rickles RJ, Schreiber SL. Specific interactions outside the proline-rich core of two classes of Src homology 3 ligands. Proc Natl Acad Sci USA 1995; 92: 12408-15.
119. Tiwari R, Brown A, Narramaneni S, Sun GQ, Parang K. Synthesis and evaluation of conformationally constrained peptide analogues as the Src SH3 domain binding ligands. Biochimie 2010; 92: 1153-1163.
120. Alfaro-Lopez J, Yuan W, Phan BC, Kamath J, Lou Q, Lam KS, Hruby VJ. Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographical constraints in peptide design. J Med Chem 1998; 41: 2252-60.
121. McMurray JS, Budde RJ, Ke S, et al. Cyclic peptides as probes of the substrate binding site of the cytosolic tyrosine kinase, pp60csrc. Arch Biochem Biophys 1998; 355: 124-30.
122. Wang W, Ramdas L, Sun G, Ke S, Obeyesekere NU, Budde RJ, McMurray JS. Cyclic peptides incorporating 4-carboxyphenylalanine and phosphotyrosine are potent inhibitors of pp60(c-)(src). Biochemistry 2000; 39: 5221-8.
123. Kumar A, Ye GF, Wang YH, Lin XF, Sun GQ, Parang K. Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as src tyrosine kinase inhibitors. J Med Chem 2006; 49: 3395-3401.
124. Goncalves V, Gautier B, Garbay C, Vidal M, Inguimbert N. Structure-based design of a bicyclic peptide antagonist of the vascular endothelial growth factor receptors. Journal of Peptide Science 2008; 14: 767-772.
125. Goncalves V, Gautier B, Garbay C, Vidal M, Inguimbert N. Development of a chemiluminescent screening assay for detection of vascular endothelial growth factor receptor 1 ligands. Anal Biochem 2007; 366: 108-10.
126. Vicari D, Foy KC, Liotta EM, Kaumaya PTP. Engineered Conformation-dependent VEGF Peptide Mimics Are Effective in Inhibiting VEGF Signaling Pathways. Journal of Biological Chemistry 2011; 286: 13612-13625.
127. Senel S, Kremer M, Nagy K, Squier C. Delivery of bioactive peptides and proteins across oral (buccal) mucosa. Curr Pharm Biotechnol 2001; 2: 175-86.
128. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007; 2: 751-60.
129. Morishita M, Peppas NA. Is the oral route possible for peptide and protein drug delivery? Drug Discov Today 2006; 11: 905-10.
130. Stolnik S, Shakesheff K. Formulations for delivery of therapeutic proteins. Biotechnol Lett 2009; 31: 1-11.
131. Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diabet Med 2003; 20: 886-98.
132. Johnson PH, Quay SC. Advances in nasal drug delivery through tight junction technology. Expert Opin Drug Deliv 2005; 2: 281-98.
133. Roach P. New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations. Clin Pharmacokinet 2008; 47: 595-610.
134. Azzariti A, Porcelli L, Simone GM, et al. Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. Cancer Chemother Pharmacol 2010; 65: 335-46.
135. Brozik A, Hegedus C, Erdei Z, et al. Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance? Expert Opin Drug Metab Toxicol 2011; 7: 623-42.